Georgina Venetia Long AO FRACP is Co-Medical Director of the Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. [1]
Long is the first woman and the first Australian to be president of the world’s largest association of melanoma researchers and scientists, the US-based Society for Melanoma Research. [2] She has authored over 300 publications in melanoma clinical and translational research, including papers in the New England Journal of Medicine and The Lancet, and has presented at hundreds of international conferences. [3] Long has also been recognised as one of the 100 Influential Women in Oncology by OncoDaily. [4]
She became 2024 Australian of the Year alongside Co-Medical Director Professor Richard Scolyer. [5]
Long grew up in a family of six children, with parents working in academia and medicine. Her early life was spent living in Europe and the United States. [6]
Long has conducted many clinical trials in melanoma, including adjuvant and metastatic melanoma.[ clarification needed][ citation needed] Long has also researched immuno-oncology, which she says is the ‘penicillin moment’ which will be able to turn cancers into ‘treatable conditions’. [7] She has focussed on immuno-oncology in melanoma and targeted therapies.[ citation needed] She also developed, and is in charge of, the treat-excise-analyse-melanoma (TEAM) program, which works on mechanisms of drug sensitivity and resistance. [8]
According to MIA's CEO Matthew Browne, 'Hardly a week goes by without a melanoma patient or their family expressing their gratitude for Professor Long’s ground-breaking research and clinical trials which have afforded them or their loved ones valuable extra time, and in many cases, a new chance at life.' 'She is a true role model for all young Australians, particularly young women, who may be working towards a career in science and medicine.' [9] Two babies have been named after the MIA and Long. [10]
Georgina Venetia Long AO FRACP is Co-Medical Director of the Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. [1]
Long is the first woman and the first Australian to be president of the world’s largest association of melanoma researchers and scientists, the US-based Society for Melanoma Research. [2] She has authored over 300 publications in melanoma clinical and translational research, including papers in the New England Journal of Medicine and The Lancet, and has presented at hundreds of international conferences. [3] Long has also been recognised as one of the 100 Influential Women in Oncology by OncoDaily. [4]
She became 2024 Australian of the Year alongside Co-Medical Director Professor Richard Scolyer. [5]
Long grew up in a family of six children, with parents working in academia and medicine. Her early life was spent living in Europe and the United States. [6]
Long has conducted many clinical trials in melanoma, including adjuvant and metastatic melanoma.[ clarification needed][ citation needed] Long has also researched immuno-oncology, which she says is the ‘penicillin moment’ which will be able to turn cancers into ‘treatable conditions’. [7] She has focussed on immuno-oncology in melanoma and targeted therapies.[ citation needed] She also developed, and is in charge of, the treat-excise-analyse-melanoma (TEAM) program, which works on mechanisms of drug sensitivity and resistance. [8]
According to MIA's CEO Matthew Browne, 'Hardly a week goes by without a melanoma patient or their family expressing their gratitude for Professor Long’s ground-breaking research and clinical trials which have afforded them or their loved ones valuable extra time, and in many cases, a new chance at life.' 'She is a true role model for all young Australians, particularly young women, who may be working towards a career in science and medicine.' [9] Two babies have been named after the MIA and Long. [10]